Diary - News
All news New members
|
Creation date Number of employees Physical location
|
Who are you ? Lys Therapeutics is a biotech company developing innovative drugs to treat patients suffering from neurological diseases, including Stroke, Multiple Sclerosis, as well as other neurodegenerative disorders. Our main drug is a first-in-class monoclonal antibody, Glunozumab®, with a unique and groundbreaking mechanism of action. In the pathophysiology of neurological diseases such as stroke or multiple sclerosis, one protease called tissue plasminogen activator (tPA) triggers off-target toxicity via hyperactivation of NMDA receptors (NMDAr) causing deleterious increase of the permeability of the blood brain barrier and strong neuronal excitotoxicity. By blocking the interaction between tPA and NMDA receptors Glunozumab® counteracts this tPA-dependent strong toxicity, hence preventing the induced neurotoxicity, neuroinflammation and blood brain barrier issues, without perturbing basal NMDAr functioning. The clinical development of Glunozumab® biotherapy is of priority for Lys Therapeutics, as a game changer for patients suffering from neurological disorders with high unmet medical needs, for a potential major societal impact. More information on lystherapeutics.com Press Contact : Agence Acorelis – Gilles Petitot / +33 620 276 594 / +33 145 831 384 gilles.petitot@acorelis.com
|
|
Creation date Number of employees Physical location
|
Who are you ? With more than 15 years of experience in academic and industrial research, CYPATH-RB is a company dedicated to research and development in pathology. Part of the CYPATH Group, which analyzes more than 700,000 samples per year, CYPATH-RB provides researchers, pharmaceutical groups or CROs with human biological samples analyzed as part of the treatment. CYPATH-RB thus provides digitized slides (HE and / or HES) as well as biological samples (FFPE, +/- fresh tissue) annotated on the histopathological, molecular +/- clinical level. CYPATH-RB also offers technical and medical services on murine models, whether in tumor pathology or in toxicopathology (ERT label). Finally, CYPATH-RB has specialized in the co-development and clinical validation of artificial intelligence tools in pathology, wishing to become a major player in digital pathology and clinical research in France. The 100% digital turn for all routine diagnostics of the CYPATH group is part of this desire.
Why did you became a Lyonbiopole's member ?
Marie Brevet, MD, PhD, Pathologiste, General Director CYPATH-RB
|
|
|
Wishing to become a major player in clinical research in France, in particular via digital pathology and the clinical validation of artificial intelligence tools in pathology, CYPATH-RB is currently seeking to extend its links with, on the one hand, companies involved in AI / digital pathology and other parts of clinical research actors (health establishments, CRO, pharmaceutical industries, etc.)."